GRCE: FY:25 Second Quarter Results
Grace is a clinical-stage, biotechnology company focused on rare disease. Its lead program, GTX-104, is a novel injectable formulation of...
124 Views
Grace Therapeutics, Inc: Initiating Coverage – From Confusion to Infusion
Grace is a clinical-stage, biotechnology company focused on rare disease.Its lead program is for GTX-104, a novel injectable formulation of...
125 Views
Acasti Pharma Inc (ACST) - Wednesday, Jul 10, 2024
Acasti Pharma is making progress in developing IV nimodipine for acute subarachnoid hemorrhages. Lead asset GTX-104 is the primary focus of their...
139 Views
No more insights